A method for the diagnosis, prognosis, stratification and / or monitoring of progression of neurotoxicityin a subject

By measuring CXCR6 and CXCL16 biomarkers in biological samples, the method diagnoses and manages neurotoxicity, addressing the inadequacies in current ICANS management by providing a precise diagnostic and therapeutic strategy.

WO2026238691A1PCT designated stage Publication Date: 2026-11-19WESTFAELISCHE WILHELMS-UNIVERSITAET MUENSTER
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/EP2026/063706
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-12
Filing Date
2026-05-12
Publication Date
2026-11-19

AI Technical Summary

Technical Problem

Current management strategies for neurotoxicity, particularly immune effector cell-associated neurotoxicity syndrome (ICANS), in subjects undergoing immunotherapy are inadequate, as the pathophysiology remains incompletely understood, and there is a need for effective diagnostic and therapeutic approaches.

Method used

The method involves determining the levels of CXCR6 and CXCL16 biomarkers in biological samples to diagnose, prognose, and monitor neurotoxicity, using a diagnostic kit with binding molecules for these markers, and employing therapeutic agents like steroids or CXCR6/CXCL16 binding molecules to treat or prevent neurotoxicity.

Benefits of technology

This approach provides a reliable means to identify at-risk individuals and evaluate treatment response, effectively managing neurotoxicity by targeting CXCR6 and CXCL16, thereby improving patient outcomes.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000039_0000
    Figure 00000039_0000
  • Figure 00000039_0001
    Figure 00000039_0001
  • Figure 00000040_0000
    Figure 00000040_0000
Patent Text Reader

Abstract

The present invention relates to a method for diagnosis, prognosis, stratification and / or monitoring of progression of neurotoxicity in a subject, said method comprising the steps of (i) providing a biological sample of the subject; (ii) determining the level of at least one biomarker selected from the group consisting of CXCR6 and CXCL16 in the biological sample, wherein a differential level of the at least one biomarker of (ii) compared to a control sample is indicative for the presence of neurotoxicity in the subject. Further, the present invention relates to a diagnostic kit for conducting the method of the present invention. Moreover, the present invention relates to the use of a binding molecule for CXCR6 and / or CXCL16 for identifying a subject being at risk for developing a neurotoxicity. Furthermore, the present invention is directed to a therapeutic agent for use in a method of treating or preventing neurotoxicity in a subject, said subject is characterized by: (i) a treatment with an immune therapeutic agent is intended, is conducted or has been conducted in said subject; (ii) a differential level of CXCR6 and / or CXCL16 in a biological sample of said subject compared to a control sample has been determined in said subject; wherein the therapeutic agent comprises one or more selected from a steroid, a glucocorticoid, a CXCR6 binding molecule, a CXCL16 binding molecule, an IL-6 binding molecule, an IL-6R binding molecule, and an IL-1R binding molecule. The present invention is also directed to a method for evaluating the treatment response of a subject who received a therapy for treating neurotoxicity, said method comprising: (i) providing a biological sample of a subject, (ii) determining the level of at least one biomarker selected from the group consisting of CXCR6 and CXCL16 in the biological sample, (iii) comparing the level of said at least one biomarker in (ii) with a reference sample or reference value; wherein a decrease of the level of the biomarker in the biological sample from said subject compared to said reference sample or reference value is indicative for a treatment response of the subject to said therapy.
Need to check novelty before this filing date? Find Prior Art

Description

New PCT ApplicationApplicant: Universitat MunsterOur Ref.: UKM18612PCTA method for the diagnosis, prognosis, stratification and / or monitoring of progression of neurotoxicity in a subjectThe present application claims the benefit of priority of EP Patent Application EP 25175629.2 filed on 12 May 2025, the content of which is hereby incorporated by reference in its entirety for all purposes.TECHNICAL FIELD OF THE INVENTION

[0001] The present invention relates to a method for diagnosis, prognosis, stratification and / or monitoring of progression of neurotoxicity in a subject, said method comprising the steps of (i) providing a biological sample of the subject; (ii) determining the level of at least one biomarker selected from the group consisting of CXCR6 and CXCL16 in the biological sample, wherein a differential level of the at least one biomarker of (ii) compared to a control sample is indicative for the presence of neurotoxicity in the subject. Further, the present invention relates to a diagnostic kit for conducting the method of the present invention. Moreover, the present invention relates to the use of a binding molecule for CXCR6 and / or CXCL16 for identifying a subject being at risk for developing a neurotoxicity. Furthermore, the present invention is directed to a therapeutic agent for use in a method of treating or preventing neurotoxicity in a subject, said subject is characterized by: (i) a treatment with an immune therapeutic agent is intended, is conducted or has been conducted in said subject; (ii) a differential level of CXCR6 and / or CXCL16 in a biological sample of said subject compared to a control sample has been determined in said subject; wherein the therapeutic agent comprises one or more selected from a steroid, a glucocorticoid, a CXCR6 binding molecule, a CXCL16 binding molecule, an IL-6 binding molecule, an IL-6R binding molecule, and an IL-1 R binding molecule. The present invention is also directed to a method for evaluating the treatment response of a subject who received a therapy for treating neurotoxicity, said method comprising: (i) providing a biological sample of a subject, (ii) determining the level of at least one biomarker selected from the group consisting of CXCR6 and CXCL16 in the biological sample, (iii) comparing the level of said at least one biomarker in (ii) with a reference sample or reference value; wherein a decrease of the level of the biomarker in the biological sample from said subject compared to said reference sample or reference value is indicative for a treatment response of the subject to said therapy.BACKGROUND ART

[0002] Tumor therapies currently often comprise besides of chemotherapeutic approaches the use of immunotherapies, i.e. the treatment with an immunotherapeutic agent. Such immunotherapies comprise in particular immune effector cell therapeutic agent or T cell engaging therapeutic agent. The principle of such T cell engaging therapeutic agents foresees that T cells are directed to tumor cells via binding to specific cell surface proteins on the tumor cell. Thereby resulting in specific elimination of the tumor cell. Chimeric antigen receptors (CARs) are synthetic transmembrane proteins that are genetically constructed to specifically recognize distinct antigenic epitopes on the surface of the tumor cells. Accordingly, chimeric antigen receptor T cells (CAR T cells), a distinct example of immunotherapeutic agents, are genetically engineered T cells that produce a receptor having the ability to bind to a specific protein. CAR T cell therapies are of particular interest for use in immunotherapy as they can be developed and produced to target and recognize cancer cells specifically. Besides CAR T cells, bispecific antibodies represent an alternative immunotherapy. Bispecific antibodies allow activating tumor-targeted T cells by binding tumor cell receptors on the one hand side, and recruiting cytotoxic immune cells on the other hand side.

[0003] CAR T cell therapy and bispecific antibodies can induce multiple adverse effects, among which cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) are especially threatening and potentially lethal1-3. Presently, antibody-drug conjugates (ADCs) are also a promising approach in cancer treatment. Several new ADC formats have been recently developed, such as bispecific ADCs, conditionally active ADCx, also known as probody-drug conjugates), immune-stimulating ADCs, protein-degrader ADCs and dual-drug ADCs (Tsuchikama et al., Nature Reviews Clinical Oncology, Volume 21, March 2024, 203-223). Anti-CD19 targeting CAR T cell treatment for leukemia and non-Hodgkin’s lymphoma as well as CAR against other antigens, and other autoimmune diseases, has been associated with severe ICANS, including fatal cerebral edema4-6. However, despite its critical significance, ICANS remains incompletely understood and current management strategies primarily revolve around corticosteroids2and blockade of interleukin-6 receptor (IL-6R) and interleukin-1 receptor (IL-1R), utilizing tocilizumab7and anakinra8. CAR T cells can migrate and persist in cerebrospinal fluid (CSF)9, but whether activated CAR T cells in the CSF directly trigger ICANS remains unclear. Some studies do not find any correlation between CAR T cell levels and ICANS severity10, while others suggest that neurotoxic severity might be more closely related to CSF cytokine levels than to CSF CAR T cell levels11.

[0004] The pathophysiology of neurotoxicity, in particular ICANS involves multiple contributing factors. Emerging evidence emphasizes the role of activated endothelial and myeloid cells in the development of ICANS, with increased blood-brain barrier (BBB) permeability facilitating theinfiltration of peripheral immune cells and cytokines into the CNS612. This infiltration may trigger local inflammation, astrocyte injury, and microglial activation. It has been shown that CAR T cells may target cerebral CD19-expressing pericytes, thereby disrupting the BBB and further exacerbating ICANS13. However, neurotoxicity is also observed in CAR T-cell therapies targeting B-cell maturation antigen (BCMA)14, indicating that the syndrome is not solely dependent on the target antigen.

[0005] There is a need to provide means and methods for the diagnosis of neurotoxicity in a subject who is at risk to develop a neurotoxicity, in particular a neurotoxicity in view of a therapeutic intervention based on immunotherapy. Therefore, the technical problem underlying the present invention is to provide a solution to the afore-mentioned needs.

[0006] Said technical problem is solved by the present invention as defined in the claims.SUMMARY OF THE INVENTION

[0007] A first subject-matter of the present invention is the provision of a method for diagnosis, prognosis, stratification and / or monitoring of progression of neurotoxicity in a subject, said method comprising the steps of: (i) providing a biological sample of the subject; (ii) determining the level of at least one biomarker selected from the group consisting of CXCR6 and CXCL16 in the biological sample, wherein a differential level of the at least one biomarker of (ii) compared to a control sample is indicative for the presence of neurotoxicity in the subject.

[0008] A second subject-matter of the present invention comprises a diagnostic kit for conducting the method of the present invention, the kit comprising binding molecules for CXCR6 and / or CXCL16 and optional suitable means for detection.

[0009] A third subject-matter of the present invention comprises a use of a binding molecule for CXCR6 and / or CXCL16 for identifying a subject being at risk for developing a neurotoxicity, preferably wherein the neurotoxicity is selected from ICANS, ICANS-like neurotoxicity or non-ICANS neurotoxicity

[0010] A fourth subject-matter of the present invention comprises therapeutic agent for use in a method of treating or preventing neurotoxicity in a subject, said subject is characterized by: (i) a treatment with an immune therapeutic agent is intended, is conducted or has been conducted in said subject; (ii) a differential level of CXCR6 and / or CXCL16 in a biological sample of said subject compared to a control sample has been determined in said subject; wherein the therapeutic agent comprises one or more selected from a steroid, a glucocorticoid, a CXCR6 binding molecule, CXCL16 binding molecule, an IL-6 binding molecule, an IL-6R binding molecule, and an IL-1 R binding molecule .

[0011] A fifth subject-matter of the present invention comprises a method for evaluating the treatment response of a subject who received a therapy for treating neurotoxicity, said method comprising: (i) providing a biological sample of a subject, (ii) determining the level of at least one biomarker selected from the group consisting of CXCR6 and CXCL16 in the biological sample, (iii) comparing the level of said at least one biomarker in (ii) with a reference sample or reference value; wherein a decrease of the level of the biomarker in the biological sample from said subject compared to said reference sample or reference value is indicative for a treatment response of the subject to said therapy.BRIEF DESCRIPTION OF THE FIGURES

[0012] Fig. 1 depicts the landscape of immune populations in the CSF of ICANS patients. (A) UMAP plot showing 6 grey-color-coded cell types of CSF cells from ICANS patients (N = 7, cell count = 5,148) and IIH control donors (N = 4, cell count = 3,513). DC: dendritic cells. CAM: CNS-associated myeloid cells. (B) Proportions of cells split by samples (N = 11). (C) Volcano plot depicting changes in cell type abundances in ICANS_onset (N = 5) versus IIH (N = 4). A minimum threshold of 25% abundance and a Iog2 fold change (logFC) of 0.25 were applied. Statistical significance calculated via propeller t-test, which uses a moderated t-statistic based on the robust empirical Bayes method from limma. P-values were adjusted with the Benjamini-Hoch method. Logarithmic fold change of cluster abundance is plotted against negative logarithmic adjusted p-value. (D) Expression of CAR_transcript gene overlaid onto the UMAP. (E) Expression of CXCR6 gene overlaid onto the UMAP. (F-G) Fraction of CAR_transcript- (E) and CXCR6- (F) expressing cells per sample stratified by cell types. Each circle / triangle represents a sample. Data are depicted as median, and the lower quartile and upper quartile. Whisker include 1.5 times the interquartile range. Unpaired two samples t-test and the bonferroni method is used to calculate the p-values. (H) Differential gene expression analysis showing up- and down-regulated genes across all six cell types between ICANS_onset (N = 5) versus IIH (N = 4) samples. P-values were adjusted with the Benjamini-Hoch method. (I) Enrichment analysis of differential KEGG pathways in the Proliferating, Cytotoxic CD4, and CD4 cell types of ICANS_onset (N = 5) versus IIH (N = 4) samples. (J) Network based on proportions of TCR clones shared between Proliferating cells with other T cells. P-values were adjusted with the Bonferroni method.

[0013] Fig. 2 depicts CXCL16-CXCR6 axis mediates T cell infiltration into the CNS during ICANS. (A) Altered Proliferating-associated, Cytotoxic CD4-associated, and CD4-associated signaling pathways in IIH versus ICANS_onset. The x and y axes indicate differential outgoing and incoming interaction strengths, respectively. (B) Circle plots of the significant interactions (ligand-receptor pairs) in the selected ICANS specific signaling networks from (A), including CXCL16-CXCR6 of the CXCL signaling pathway, IL16-CD4 of the IL16 signaling pathway, and CD40LG-(ITGAM+ITGB2) of the CD40 signaling pathway. (C) Representative Image and Comparison of CD4 / CD8 ratios between paired CSF and PBMC between paired CSF and PBMC by flow cytometry. (D) The percentage of CAR+CXCR6+ cells within CD4 T cells between paired CSF and PBMC, segmented by patient groups: ICANS_onset (N = 7) and IIH control (N = 7). Representative Images depicted as a bivariate overlay plot of CSF and PBMC samples of ICANS_onset and IIH. Each circle represents a sample. Data are depicted as median, and thelower quartile and upper quartile. Whisker include 1.5 times the interquartile range. Statistical significance calculated via paired t-test with the Holm-Bonferroni correction method for p-value adjustments. (E) Boxplot representing CXCL16 concentration (ng / ml) in the CSF of ICANS_onset patients (N = 10) across different ICANS grades. Data are shown as median with lower and upper quartiles. Whiskers represent 1.5 times the interquartile range. Statistical significance was assessed using the Kruskal-Wallis test with post hoc Dunn's test for p-value adjustment. (F) Scatter plots depicting spearman correlations of CSF CXCL16 level with clinical ICANS severity in ICANS_onset patients (N = 10) and (G) CSF IL-6 levels, if available (N = 7) with ICANS grade.

[0014] Fig. 3 depicts CXCR6+ T cells and CXCL16+ myeloid cells in the choroid plexus and brain parenchyma of one post-mortem ICANS patient. (A) CXCL16 and CXCR6 immunohistochemistry of the ICANS choroid plexus (scale bar, 50 pm). (B) Multiplexed immunofluorescence staining (left) and DAPI single staining of one representative post-mortem ICANS brain parenchyma. White reticular boxes indicate the areas detailed in panels (C) and (D). CD3, CXCR6, DAPI (white), CXCL16, and CD11b. Scale bar: 20 pm. (C) High-resolution image highlighting CD11b+CXCL16+ cells in panel B, stained for CD11b, CXCL16, and IL-18. Scale bar: 10 pm. (D) High-resolution image highlighting CD3+CXCR6+ cells in panel B, stained for CD3, CXCR6, and Ki-67. Scale bar: 10 pm. (E) Ratio of CXCR6+ T cells to CXCL16+ or CXCL16-myeloid cells within a 100 pm radial distance in four brain parenchyma regions (1000 x 1000 pm areas) from a post-mortem ICANS brain (N = 1). Data are depicted as median, and the lower quartile and upper quartile. Whisker include 1.5 times the interquartile range. Statistical significance calculated via paired t-test with the Holm-Bonferroni correction method for p-value adjustments. The diagram was created in BioRender. Lu, I. (2025) https: / / BioRender.com / w42c592.

[0015] Fig. 4 depicts disease course of ICANS patients (A) Swimmer plot depicting the CAR treatment (brexu-cel (cross), axi-cel (square), cilta-cel (circle)) and post CAR treatment follow up (light grey bar). Bars depict the clinical signs and symptoms of ICANS (black) and CRS (dark grey). Timeline of CSF withdrawals (CSF) and magnetic resonance imaging (MRI) across the clinical follow up are additionally shown in light grey. Box plots showing (B) cell count and (C) total protein in the CSF of ICANS and control patients. (D) Scatter plot showing a correlation (Spearman) of Serum IL-6 levels relative to the max CRS level.

[0016] Fig. 5 depicts classification of CSF cell types. (A) The UMAP plot on the left illustrates 23 color-coded clusters of CSF cells from ICANS patients (N = 7, cell count = 5,148) and IIH control donors (N = 4, cell count = 3,513). These clusters are utilized for the subsequent assignment of cell types depicted in the UMAP plot below. (B) Dot plot showing marker genes ofcell types. Greyscale color encodes average gene expression; dot size represents percentage of cells expressing the gene. (C) Cell proportions in clusters across 11 individual samples. Absolute cell counts for each cluster are indicated in parentheses. (D) Fraction of GZMA- expressing cells per cell type stratified by clusters. Absolute counts of GZMA+ cells for each cluster are indicated in parentheses.

[0017] Fig. 6 depicts CSF cell characteristics during ICANS onset. (A) Fraction of cells per sample stratified by cell cycle phases. Each circle / triangle represents a sample. Data are depicted as median, and the lower quartile and upper quartile. Whisker include 1.5 times the interquartile range. Unpaired two samples t-test and the bonferroni method is used to calculate the p-values.(B) Heatmap showing gene set enrichment results as estimating ssGSEA scores across all cell types of ICANS_onset patients and IIH control donors. (C) Composition of Proliferating cell clusters across samples.

[0018] Fig. 7 depicts CXCR6 expression correlates with enhanced T cell cytotoxicity. (A) Violin plots comparing the normalized CXCR6 expression levels across various T cell subsets between ICANS_onset and IIH samples. (B) Correlation plot showing the relationship between CXCR6 and GZMA expression in different T cell populations (grouped and colored with greyscale by CD4, Cytotoxic CD4, CD8, and Proliferating T cells) from ICANS_onset patients. A significant positive correlation is observed between CXCR6 and GZMA across all T cell populations, with the highest correlation found in CD4 and Cytotoxic CD4 cells (R and p-values indicated). Values on the x- and y-axes represent the percentage of gene counts attributed to CXCR6 (x-axis) and GZMA (y-axis) for each cell. These percentages were calculated using the 'PercentageFeatureSet' function in the Seurat package.

[0019] Fig. 8 depicts TCR clonal expression in the CSF T cells during ICANS onset. (A) UMAP plots depicting the distribution of total CSF TCR clones with a clonal frequency over 1%.(B) Relative proportion of TCR clones between ICANS_onset and IIH.

[0020] Fig. 9 depicts longitudinal alteration in the CSF immune landscape. (A) CXCL16 cytokine concentration (pg / mL) measured in the CSF derived from patient ICANS1 during pre-CART infusion, ICANS_onset, and ICANS_remission (N = 1, technical replicates = 2). (B) Fractions of CAR_transcript- and CXCR6-expressing CSF cells during pre-CART infusion, ICANS_onset, and ICANS_remission of ICANS1 patient (N = 1) stratified by cell types. (C) Differentially expressed genes in ICANS_onset versus pre-CART infusion. Statistical significance was calculated in limma using a moderated t-statistic based on the robust empirical Bayes method in limma. P values were adjusted with the Benjamini-Hochberg method.

[0021] Fig. 10 depicts CXCR6 localizes predominantly on CD4 CAR CSF cells. (A) CD4 and (B) CD8 T cells in the ICANS_onset (N = 7) and control donors (N = 7). (C) shows percentage of CAR T cells in CD4 and CD8 populations. (D) Comparison of CXCR6+CAR+ and CXCR6+CAR-cells in CD4 T cells. (E) Comparison of CAR+CXCR6+CD8 T cells in CSF and PBMC of ICANS_onset and control patients (F) Depiction of CXCR6+CAR+ and CXCR6+CAR- cells in CD8 T cells in the ICANS_onset cohort. Box plots showing percentage of respective population depicted on the y-axis in CSF (left) and PBMC (right) as measured by flow cytometry. Gating scheme as shown in Figure 12. Individual data points are shown using overlaid dot plots, gray lines connect paired samples. Data are depicted as median, and the lower quatile and upper quartile. Whisker include 1.5 times the interquartile range. If more than two groups were compared a Kruskal-Wallis with post hoc Dunn test was performed, if else paired t-test was calculated for statistical significance.

[0022] Fig. 11 depicts longitudinal flow cytometry analysis demonstrates a selective increase in CXCR6+CAR+ CD4 T cells during ICANS but not during CRS. (A) Gating strategy used to identify CD4 and CD8 T cells. (B) Contour plots displaying the expression levels of CXCR6 and CAR in CD4 (top) and CD8 (bottom) T cells on day 0 (DO, CART product), day 1 (D1, no adverse event), day 2 (D2, CRS), and day 5 (D5, ICANS) post-CART infusion, analyzed in PBMC or CSF. (C) Line graph illustrating the temporal dynamics of CAR+CXCR6+ CD4 and CD8 T cells, alongside serum IL-6 levels, in relation to days post-CAR infusion. Shaded regions indicate the occurrence of CRS (light grey) and ICANS (dark grey). Vertical lines mark the timing of CAR infusion and the treatments administered during CRS and ICANS.

[0023] Fig. 12 depicts CSF CD4 CAR cells show a significant increase of activation markers in ICANS_onset patients. Boxplots showing percentage of (A, C) GZMA+ and (B, D) CD69+ by CAR status in (A, B) CD4 and (C, D) CD8 T cells in the ICANS_onset (N = 7) cohort in CSF (left) and PBMC (right) measured by flow cytometry. (E-G) Expression of (E) CXCR6, (F) GZMA and (G) CD69 is compared in CAR positive and CAR negative cells in the CD4 and CD8 T cell compartment of ICANS_onset CSF (N = 7). Gating scheme as shown in Figure 11. Individual data points are shown using overlaid dot plots, gray lines connect paired samples. Data are depicted as median, and the lower quatile and upper quartile. Whisker include 1.5 times the interquartile range. A paired t-test was calculated for statistical significance.

[0024] Fig. 13 depicts CXCL16 correlates with ICANS severity. (A) Boxplot representing CXCL16 concentration in ng / ml in the CSF of different cohorts, including control: N = 7, multiple sclerosis (MS): N = 7, and ICANS_onset samples: N = 9. Data are depicted as median, and the lower quatile and upper quartile. Whisker include 1.5 times the interquartile range. (B) Scatterplots depicting spearman correlations of (B) CSF IL-6 levels, if available (N = 7) with ICANS grade. The line depicts the linear regression and R is showing the correlation coefficient.

[0025] Fig. 14 depicts phenotyping of myeloid cells in ICANS patients. (A-H) Spatial transcriptomic of postmortem choroid plexus from an ICANS patient with spatial distributions of (A) CXCL16, (B) CD14, (C) CD40, (D) CD68, (E) ITGAL, (F) ITGA4, (G) CX3CR1, and (H) TMEM1119 genes in a 6.5 x 6.5 mm capture area with 8-pm pixel size by VisiumHD. (I) Explorative flow cytometric analysis with contour plots and gating scheme displaying the expression levels of CD40 and CD49d in monocytes in an ICANS patient, analyzed in PBMC or CSF.

[0026] Fig. 15 depicts detection of CXCL16-CXCR6 axis in the postmortem ICANS brain. (A) Overview image showing four regions of interest (ROIs), each 1000 x 1000 pm, with T cell infiltration. These ROIs were selected for proximity analysis in Fig. 3E and are located within the brain parenchyma of a post-mortem ICANS case (N = 1). Scale bar: 1000 pm. (B) Multiplexed immunofluorescence staining in an additional representative field of post-mortem ICANS brain parenchyma. CD3, CXCR6, DAPI (white), CXCL16, and CD11b. Scale bar: 20 pm.

[0027] Fig. 16 depicts up-regulated genes related to CAR-transcript expression in the CSF T cell subsets during ICANS. (A-B) LIMAP representation of dataset from ICANS_onset patients (N = 5, cell count = 4,716) and IIH control donors (N = 4, cell count = 3,513), grey-colored by CAR-transcript expression (A) and CAR+ or CAR- T cell populations (B). (C-F) DEGs with top markers and CXCR6 highlighted in all T cell populations (CD4, Cytotoxic CD4, Proliferating, and CD8) of CAR+ versus CAR- cells. The horizontal lines represent the significance thresholds (horizontal dashed line: P = 0.05).DETAILED DESCRIPTION OF THE INVENTION

[0028] The solution of the present invention is described in the following, exemplified in the appended examples, illustrated in the Figures and reflected in the claims.

[0029] The present invention provides in a first subject-matter a method for diagnosis, prognosis, stratification and / or monitoring of progression of neurotoxicity in a subject, said method comprising the steps of (i) providing a biological sample of the subject; (ii) determining the level of at least one biomarker selected from the group consisting of CXCR6 and CXCL16 in the biological sample, wherein a differential level of the at least one biomarker of (ii) compared to a control sample is indicative for the presence of neurotoxicity in the subject.

[0030] The inventors have been able to identify CXCR6 and CXCL16 as biomarkers for identifying neurotoxicity. This finding appears surprising since CXCR6 and CXCL16 have not been described or thought to be associated in the context of neurotoxicity so far.

[0031] CXCL16 is classified as an a sub-family chemokine in view of a CXC motif at the N-terminus. It exists as membrane-bound form mCXCL16 and as soluble form sCXCL16. CXCL16 is expressed in lymphoid organs such as the thymus, spleen, lymph nodes, and Peyer’s patches, but CXCL16 is not expressed in bone marrow. It is also expressed in the liver, lung, small intestine, and kidney. Moreover, CXCL16 is highly expressed in the epidermis, where it is produced by keratinocytes. The membrane-bound form mCXCL16 is expressed in macrophages and is also present in splenic and lymph node dendritic cells (DC), blood myeloid DC, and monocyte-derived DC. Both forms of CXCL16 have different functions. sCXCL16 is a chemokine that is responsible for the chemotaxis of cells bearing the CXCR6 receptor while mCXCL16 is a transmembrane protein. The membrane-bound form mCXCL16 may have adhesion protein properties that bind to CXCR6.

[0032] Apart from mCXCL16, the only receptor for SCXCL16 is CXCR6. CXCR6 is highly expressed in the appendix, lymph node, placenta, spleen, and thymus. Therein, CXCR6 is expressed on immune system cells, in particular, naive CD8+cells, CD3"CD16" / |OWCD56+and CD3"CD16|OWCD56" natural killer (NK) cells, natural killer T (NKT) cells, activated CD4+and CD8+T cells, and in 30-40% of y<5 T cells. Structurally, CXCL16 is a member of the CXC chemokine subfamily. Different to other members of this subgroup, CXCL16 is structurally different and comprises four distinct domains: a chemokine domain attached to the cell surface via a mucinlike stack, which is in turn attached to transmembrane and cytoplasmic domains. CXCL16 attracts CXCR6 expressing T, NK, and NKT cells to the site of inflammation / injury. It has been shown that human aortic smooth muscle cell express CXCR6 and that treatment with CXCL16 activates NF-KB via heterotri meric G proteins / PI3K / PDK-1 / Akt / IKK / lKB, which in turn increases cell-cell adhesion and cellular proliferation (B.S. Chandrasekar, S. Mummidi, CXCL16 signals via Gi, phosphatidylinositol 3-kinase, Akt, IKB kinase, and nuclear factor-KB and induces cell-celladhesion and aortic smooth muscle cell proliferation, J. Biol. Chem. 279 (2003) 3188-3196.). Further, it has been shown that CXCR6 is involved in the recruitment of CXCR6+ leukocytes into the atherosclerosis-prone aortic wall in form of short-term homing experiments. These data provide evidence for a proatherosclerotic role of CXCR6. Absence of CXCR6 alters the recruitment of CXCR6+ leukocytes and modulates the local immune response within the aortic wall (E. Galkina, B.L. Harry, A. Ludwig, E.A. Lieh, J.M. Sanders, A. Bruce, C. Weber, K. Ley, CXCR6 promotes atherosclerosis by supporting T-cell homing, interferon production, and macrophage accumulation in the aortic wall, Vase. Med. 116 (2007) 1801-1811.). Moreover, the CXCL16 mediated adhesion of CXCR6 expressing cells has been shown, which demonstrates that CXCL16 is a unique molecule that not only attracts T cells and NKT cells toward DCs but also supports their firm adhesion to DCs (T. Shimaoka, T. Nakayama, N. Fukumoto, N. Kume, S. Takahashi, J. Yamaguchi, M. Minami, K. Hayashida, T. Kita, J. Ohsumi, O. Yoshie, S. Yonehara, Cell surface-anchored SR-PSOX / CXC chemokine ligand 16 mediates firm adhesion of CXC chemokine receptor 6-expressing cells, J. Leukoc. Biol. 75 (2003) 267-274.). Furthermore, it has been shown that CXCR6+ platelets from flowing blood attach to CXCL16 expressed by activated endothelium on the luminal side of the blood vessel. Additional studies provided the findings that platelets bound to the inflamed endothelium are presenting CXCR6 to CXCL16-positive peripheral blood mononuclear cells (PBMCs) and, thus, are mediating an increased adhesion of PBMCs to the arterial wall. Furthermore, it has been identified that endothelial CXCL16 as an important adhesion molecule promoting the firm adhesion of CXCR6-positive PBMCs to inflamed endothelium. Thus, it has been demonstrated that endothelial CXCL16 as well as platelet CXCR6 are acting as potent PBMC-adhesion ligands, inducing PBMC-adhesion to the atherosclerosis-prone vessel wall and thus promoting the progression of atherosclerosis (Bona Linke, Sascha Meyer Dos Santos, Bettina Picard-Willems, Michael Keese, Sebastian Harder, Gerd Geisslinger, Klaus Scholich, CXCL16 / CXCR6-mediated adhesion of human peripheral blood mononuclear cells to inflamed endothelium, Cytokine, Volume 122, 2019, 154081, ISSN 1043-4666, https: / / doi.Org / 10.1016 / j.cyto.2017.06.008.).

[0033] The term “differential level” according to the present invention is understood as a difference in the expression of the at least one biomarker, in particular of CXCR6 and / or CXCL16. The term “differential level” according to the present invention can in particular be understood as an altered expression of the at least one biomarker. Said altered expression of the at least one biomarker may be an elevated expression or a diminished expression. The difference of the expression may be an altered expression of biomarker, such as in particular CXCR6 and / or CXCL16, which altered expression can be measured in the biological sample of the subject. Such an altered expression of the biomarker, such as in particular CXCR6 and / or CXCL16, may be an elevated gene expression of the biomarker, such as in particular CXCR6 and / or CXCL16. The altered expression of the at least one biomarker, in particular of CXCR6 and / or CXCL16, mayalso be an elevated protein expression of the biomarker. The elevated protein expression may be an elevated protein expression of the biomarker on the cell surface, or may be an elevated protein expression of the biomarker in soluble form. Accordingly, soluble and insoluble forms of protein are encompassed with the term “differential level” accordingly to the present invention.Further, an altered expression of the at least on biomarker, in particular of CXCR6 and / or CXCL16, may also or additionally be that an altered number of cells are expressing the at least one biomarker. Thus, a higher number of cells compared to total number of cells of the biological sample, or a lower number of cells compared to the total number of cells of the biological sample may be understood as encompassed as differential level according to the present invention. Said altered number of cells expressing the at least one biomarker is also known as differential abundance.

[0034] In a preferred embodiment of the present invention, it is foreseen that the subject the subject conducts or has conducted a treatment with an immune therapeutic agent, preferably an immune effector cell therapeutic agent or a T cell engaging therapeutic agent selected from a CAR-T cell, an antibody, preferably a bispecific antibody.

[0035] Chimeric antigen receptors (CARs) are synthetic transmembrane proteins that are artificially constructed with the aim that a specific antigenic epitope on the surface of a tumor cell is recognized. CARs comprise an extracellular antigen recognition domain, and an intracellular part which includes an activation domain combined with costimulatory signalling endodomains that are able to induce T cell activation upon antigen binding. CARs are constructed on the surface of the T cells of a patient’s own - physiologic - T cell in form of an ex vivo process.

[0036] In a preferred embodiment of the present invention, the CAR-T cell is directed to an antigen associated with a tumour, haematological malignancy, cancer, or autoimmune disease, preferably directed to an antigen selected from CD19, B cell maturation antigen (BCMA), CD20, CD22, CD30, CD138, CD123, NKG2DL, CD5, CD7, CD4, KISS1R, CLDN6, MUC21, MUC16, SLC6A3, QRFPR, GPR119, UPK2, ADAM12, SLC45A3, MS4A12, ALPP, SLC2A14, GS1-259H13.2, ADGRG2, ECEL1, ERVFRD-1, CHRNA2, GP2, PSG9, IL13Ra2, TAG-72, ErbB2, HER2, B7H3, PD-L1, EPCAM, NKG2D, MESO, CD70, SenL-T7, and CD79b.

[0037] Bispecific antibodies are engineered hybrid molecules with twofold binding capacity. They simultaneously bind to both a target epitope on the surface of the malignant plasma cells and on endogenous immune effector cells, which are usually T cells. The twofold binding allows the formation of an immunologic bridge which exerts the elimination of the tumor cell by the activated immune effector cell.

[0038] In a preferred embodiment of the present invention, the bispecific antibody is directed against one or more of the following antigens: CD3, CD19, CD20, EpCam, Gp100, BCMA, EGFR, cMET, PD-1, CTLA-4, FX, FIXa, HER2, and HER3.

[0039] Further preferred according to the present invention are also multispecific antibodies, such as trispecific or tetraspecific antibodies.

[0040] In a preferred embodiment of the present invention, the bispecific antibody is selected from blinatumomab, emicizumab, amivantamab, teclistamab, zenocutuzumab, catumaxomab, mosunetuzumab, tebentafusp, teclistamab, cadonilimab, and rituximab.

[0041] Antibody-drug conjugates (ADCs) are also a promising approach in cancer treatment. Several new ADC formats have been recently developed, such as bispecific ADCs, conditionally active ADCx, also known as probody-drug conjugates), immune-stimulating ADCs, proteindegrader ADCs and dual-drug ADCs (Tsuchikama et al., Nature Reviews Clinical Oncology, Volume 21, March 2024, 203-223).

[0042] In a preferred embodiment of the invention, the immune therapeutic agent is an antibodydrug conjugate.

[0043] In a preferred embodiment of the present invention, it is foreseen that the subject the subject conducts or has conducted a treatment with an immune therapeutic agent, preferably an immune effector cell therapeutic agent or a T cell engaging therapeutic agent selected from a CAR-T cell, an antibody, preferably a bispecific antibody. The term “conducts a treatment” can also be understood as a therapeutic treatment that has been initiated and that is still continued. Accordingly, the term “conducts a treatment” may also relate to a treatment which has been initiated and has been applied, but is paused before it is continued and terminated. The term “has conducted a treatment” according to the present invention can be understood as a therapeutic treatment that has been applied, and this therapeutic treatment has been terminated.

[0044] Immune therapeutic agents, in particular CAR-T cell or antibody, such as bispecific antibody have been included as new approaches besides or in addition to standard chemotherapy in subjects suffering for examples from distinct forms of leukaemia. Immune therapeutic agents, such as CAR T-cells and bispecific antibodies have been associated with distinct adverse events which can be very serious, and potentially life-threatening. Typically, adverse events associated with the CAR-T cell or bispecific antibody therapy involve neurotoxicity. In accordance with the present invention, the term “neurotoxicity” can be understood as a form of toxicity exerted directly or indirectly by a biological, chemical, or physical agent that provokes an adverse effect on the structure or function of the central nervous system and / or peripheral nervous system. Neurotoxicity arises when the exposure to a substance alters the normal activity of the nervous system in such a way as to cause permanent or reversible damage to nervous tissue.

[0045] In a further preferred embodiment of the invention the neurotoxicity is immune effector cell-associated neurotoxicity syndrome (ICANS), ICANS-like neurotoxicity or non-ICANS neurotoxicity.

[0046] Immune effector cell-associated neurotoxicity syndrome (ICANS) is probably the maincause of neurotoxicity, since most acute and early-onset of neurotoxicity is supposed to be triggered by immune effector cell-associated neurotoxicity syndrome (ICANS). ICANS has been described for example for CD19 CAR T-cell therapies for non-Hodgkin’s lymphoma or B-cell acute lymphoblastic leukemia. Although, the exact pathogenesis has not been exactly defined, it is assumed that ICANS mediated neurotoxicity is independent of the target of therapeutic CAR-T cell or of the therapeutic antibody, such as a therapeutic bispecific antibody. Possible mechanism of ICANS comprise excess cytokine release, which then leads to a cytokine-induced endothelial activation with blood-brain barrier disruption, and thus and systemic immune cell activation and infiltration into the brain and direct central nervous system (CNS) exposure to blood-circulating cytokines. Microglia are then likely activated by the series of cytokines migrating to the cerebrospinal fluid (CSF), thereby provoking secondary cytokine production and local inflammation. Additional mechanisms comprise activation of infiltrating myeloid and CAR T cells. ICANS is characterised by several symptoms. Among these the main symptoms comprise in its earliest manifestations tremor, dysgraphia, difficulties with expressive speech, impaired attention, apraxia, lethargy advancing to more severe conditions with global aphasia, hemiparesis, depressed consciousness, coma, seizures, myocloni. ICANS is graded from ICANS grade 1-4. Neurotoxicity domains include the immune-effector cell-associated encephalopathy - ICE - score, consciousness, seizure, motoric findings, elevated ICP / cerebral edema. Bispecific antibodies are also known to exert ICANS due to immune effector cell activation and the involvement of cytokine release. In general, ICANS is primarily linked to CAR-T cell therapy, and to a lesser extent to bispecific antibody therapy. Typically, bispecific antibodies do not induce the same level of systemic cytokine release compared with CAR-T cells. Nevertheless, CAR-T cells as well as bispecific antibody therapies may provoke ICANS as severe adverse effect.

[0047] In accordance with the present invention ICANS-like neurotoxicity may comprise any neurotoxicity which may be exerted by cytokine release syndrome (CRS). Cytokine release syndrome is a sequela of the overactivation of the immune response after administration of CAR-T cells or bispecific antibodies. Actually, it represents the most common nonhematologic early onset toxicity of these therapies. A very high number of cytokines, chemokines and other proinflammatory mediators are involved in the pathogenesis of CRS, with IL-6 being or particular importance. IL-6 is predominantly produced by the endogenous macrophages / monocytes and also endothelial cells, and it is involved in several physiologic functions, including regulation of chemokine / cytokine secretion, and recruitment of immune cells during inflammation, angiogenesis, and B-cell differentiation. Another crucial mediator is IL-1, also produced by macrophages / monocytes, and similar to IL-6, it possesses inflammation regulatory properties including augmentation of IL-6 secretion. Other contributing cytokines are the granulocytemacrophage colony-stimulating factor (GM-CSF) and monocyte chemoattractant protein-1 (MCP-1), which, along with TNF-a and IFN-y, play a role in migration and activation of macrophagesand monocytes to produce IL-6. Apart from IL-1 and IL-6, macrophages also produce nitric oxide and catecholamines to further increase the hyper-inflammatory immune response.

[0048] Non-ICANS neurotoxicity according to the present invention can occur, manifesting as movement and neurocognitive treatment-emergent adverse event. Non-ICANS neurotoxicity typically develops after the recovery period from CRS and / or ICANS and has a longer and oftentimes irreversible nature. It has been linked to specific CAR-T cell therapies, such as those targeting BCMA. For Non-ICANS neurotoxicity, it is suggested that mechanisms such as off-target effects or antigen expression in non-malignant tissues, e.g. basal ganglia neurons and cerebellum, may contribute. Similar mechanisms have been described for ADCs binding antigens expressed on healthy tissues or when cytotoxic payloads are released prematurely. Similar to ICANS, these phenomena are also clinically heterogeneous, and may mimic parkinsonism, with movement - such as tremor, bradykinesia, shuffling gait, apraxia, rigidity, micrographia -, cognitive, and personality changes - such as memory loss, flat affect, etc.

[0049] Preferably, it is foreseen that according to the present invention the biological sample is a sample of a subject comprising a body liquid sample, such as cerebrospinal fluid (CSF), blood, serum, plasma, lymph fluid, pleural fluid, tear fluid, urine, or a tissue sample, such as a nerve or brain biopsy, a meningeal biopsy, a skin biopsy, or a biopsy from any other tissue containing neuronal material. Thus, it is foreseen according to the invention that any biological sample is used that provides neurological material in form of protein and / or genetic information of the subject.

[0050] In a particular preferred embodiment of the invention, the biological sample is CSF.

[0051] Preferably, the method of the present invention foresees that determining of the at least one biomarker in step (ii) is conducted by one or more of the methods selected from single cell and bulk RNA sequencing, DNA sequencing, quantitative PCR, differential gene expression analysis, methylation microarrays, spatial transcriptomics, quantitative PCR, proteomic assays, multiplex proteomic assays, metabolic assays, mass spectrometry, multicolour flow cytometry, enzyme-linked immunosorbent assay (ELISA), immunohistochemistry and fluorescence in situ hybridisation (FISH).

[0052] In a preferred embodiment of the invention, step (ii) comprises one or more of the methods of single cell RNA sequencing, ELISA, and immunohistochemistry.

[0053] In accordance with the present invention, any possible method is encompassed which allows the identification and quantification of a protein, in particular in a solution. A person skilled in the art is aware which method is suitable to determine the one or more biomarker according to the invention. Thus, a skilled person is able to a suitable method for determining the biomarker on DNA / RNA level and / or on protein level.

[0054] In a preferred embodiment of the invention, it is foreseen that in step (ii) one or morefurther biomarker are determined selected from the group consisting of a CAR transcript; one or more marker of T cells, in particular selected from CD3, CD4, CD8, and FoxP3; one or more marker of myeloid cells, in particular selected from CD11a, CD11b, CD11c, CD14, CD15, CD33, CD49d, CD64, CD66b, CD68, CD115, CD155, CD163, CD206, TMEM119 and CX3CR1; one or more activation markers, in particular selected from CD25, CD69, CD127, and HLA-DR; one or more costimulatory or inhibitory markers, in particular selected from CD27, CD28, CTLA4, CD40, CD70, CD80, CD86, CD134, CD137, CD226, CD274, CD279, LAG3, TIM-3, VISTA, ICOS, TIGIT and its ligands; one or more cytotoxic markers, in particular selected from CD107a, granzymes, preferably GZMA and / or GZMB, and lysozymes; and one or more of IL (Interleukin)-I, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IL-16, IL-17, IL-18, IL-19, IL-20, IL-21, IL-22, IL-23, IL-24, IL-25, IL-26, IL-27, IL-28, IL-29, IL-31, IL-32, IL-33, IL-34, IL-35, IL-36, IL-37, IL-38 and its receptors, INF (Interferon)-alpha, INF-beta and INF gamma and its receptors, CCL1, CCL2, CCL3, CCL3L1, CCL3L3, CCL4, CCL4L1, CCL4L2, CCL5, CCL6, CCL7, CCL8, CCL9, CCL10, CCL11, CCL12, CCL13, CCL14, CCL15, CCL16, CCL17, CCL18, CCL19, CCL20, CCL21, CCL22, CCL23, CCL24, CCL25, CCL26, CCL27, CCL28, CXCL1, CXCL2, CXCL3, CXCL4, CXCL4L1, CXCL5, CXCL6, CXCL7, CXCL8, CXCL9, CXCL10, CXCL11, CXCL12, CXCL13, CXCL14, CXCL15, CXCL17, CX3CL1, XCL1, XCL2 and its receptors, Ki-67, PCNA and MCM.

[0055] According to the present invention, the one or more biomarker is selected based on the desired diagnostic. Thus, a person skilled in the art is aware which biomarker has to be chosen to achieve information concerning T cells, B cells or any other immune cell, and / or indication concerning the presence of CRS or any other cause leading to neurotoxicity. Further, any suitable biomarker for the identification of distinct neuronal cells affected by neurotoxicity, preferably myeloid cells, may be determined. In accordance with the present invention, any suitable marker capable for characterising a distinct cell type or cells, or a distinct phenotype of such cell types or cells, such as an activated or cytotoxic phenotype or genotype, is included which allows determining neurotoxicity.

[0056] In a preferred embodiment of the invention step (ii) comprises determining the further biomarkers IL-6 and / or IL-1 b. This allows discriminating between ICANS or ICANS-like due to CRS.

[0057] In a further preferred embodiment of the invention, it is foreseen that determining of further risk factors for the development of neurotoxicity is conducted, preferably by determining the score of CRS and / or ICANS.

[0058] The present invention provides in a second subject-matter a diagnostic kit for conducting a method according to the present invention, the diagnostic kit comprising binding molecules for CXCR6 and / or CXCL16 and optional suitable means for detection.

[0059] The diagnostic kit of the present invention allows to determine the presence or thelikelihood to develop a neurotoxicity in form of detecting CXCR6 and / or CXCL16 in a subject. According to the present invention, suitable means for detection comprise any suitable mean that allow the identification and thereby detection of CXCR6 and / or CXCL16 as biomarkers of neurotoxicity in a subject. For example, suitable means for detection may comprise binding molecules, such as antibodies, which are able to bind specifically to CXCR6 and / or CXCL16. Such binding molecules, such as antibodies, may be coupled with markers, which allow the detection using suitable methods. Such suitable methods are known for a person skilled in the art.

[0060] The present invention provides in a third subject-matter a use of a binding molecule for CXCR6 and / or CXCL16 for identifying a subject being at risk for developing a neurotoxicity, preferably wherein the neurotoxicity is selected from ICANS, ICANS-like neurotoxicity or non-ICANS neurotoxicity.

[0061] Accordingly, it is foreseen that a binding molecule which binds to CXCR6 and / or CXCL16 allows determining of a subject who is supposed to show neurotoxicity as adverse effect, preferably neurotoxicity which arises due to ICANS after CAR-T cell treatment of bispecific antibody treatment. According to the present invention, any suitable binding molecule which is capable of binding to CXCR6 and / or CXCL16 are encompassed. A person skilled in the art is aware of suitable CXCR6 and / or CXCL16 binding molecules, such as antibody or antibody fragments which are capable of specifically binding to CXCR6 and / or CXCL16.

[0062] The present invention provides in a fourth subject-matter a therapeutic agent for use in a method of treating or preventing neurotoxicity in a subject, said subject is characterized by: (i) a treatment with an immune therapeutic agent is intended, is conducted or has been conducted in said subject; (ii) a differential level of CXCR6 and / or CXCL16 in a biological sample of said subject compared to a control sample has been determined in said subject; wherein the therapeutic agent comprises one or more selected from steroid, glucocorticoid, CXCR6 binding molecule, CXCL16 binding molecule, IL-6 binding molecules, IL-6R binding molecules, and IL-1 R binding molecules.

[0063] According to the present invention, it is foreseen that the therapeutic agent selected from steroid, glucocorticoid, CXCR6 binding molecule and CXCL16 binding molecule is able to treat or inhibit neurotoxicity in a subject. Binding molecules, such as antibody or antibody fragments, with specificity to bind to CXCR6 and / or CXCL16 are preferred to achieve the therapeutic or prophylactic effect in view of neurotoxicity in a subject. Without to be bound to any theory, it is supposed that binding and possibly inhibiting the axis of CXCR6 to its ligand CXCL16 via CXCR6 and / or CXCL16 binding molecules may be beneficial since the expression of CXCR6 and CXCL16 appear to play a role in the development of neurotoxicity, in particular of ICANS mediated neurotoxicity. Since the inventors show that the expression of CXCR6 and / or CXCL16 correlates with an enhanced T cell cytotoxicity (see Figure 7), it is assumed that intervening the binding of CXCR6 to CXCL16 avoid neurotoxicity due to cytotoxic T cell effects. Preferred steroids orglucocorticoids are methylprednisolone or dexamethasone. The use of steroids or glucocorticoids, such as methylprednisolone or dexamethasone, is known as standard treatment or prophylaxis of neurotoxicity, preferably ICANS mediated neurotoxicity. In a preferred embodiment of the invention steroids are used alone or in combination with CXCR6 binding molecules and / or CXCL16 binding molecules. In a further preferred embodiment of the invention comprises the therapeutic agent also IL-6 binding molecules, IL-6R binding molecules, or IL-1 R binding molecules - such as siltuximab, tocilizumab, anakinra - alone or in combination with steroid, glucocorticoid, CXCR6 binding molecule, and CXCL16 binding molecule. IL-6 binding molecules, IL-6R binding molecules and IL-1R binding molecules are intended to target IL-6 and IL-1 cytokines which play a role in the development of CRS which may then lead to neurotoxicity.

[0064] In a preferred embodiment of the present invention it is foreseen that the immune therapeutic agent is an immune effector cell therapeutic agent or a T cell engaging therapeutic agent, preferably a CAR-T cell, an antibody, preferably a bispecific antibody.

[0065] Preferably, the neurotoxicity is immune effector cell-associated neurotoxicity syndrome (ICANS), ICANS-like neurotoxicity or non-ICANS neurotoxicity.

[0066] The present invention provides in a fifth subject-matter a method for evaluating the treatment response of a subject who received a therapy for treating neurotoxicity, said method comprising: (i) providing a biological sample of a subject, (ii) determining the level of at least one biomarker selected from the group consisting of CXCR6 and CXCL16 in the biological sample, (iii) comparing the level of said at least one biomarker in (ii) with a reference sample or reference value; wherein a decrease of the level of the biomarker in the biological sample from said subject compared to said reference sample or reference value is indicative for a treatment response of the subject to said therapy.

[0067] Accordingly, the present invention is directed to a method which allows determining or assessing the therapeutic effect of a treatment against neurotoxicity in a subject. Thus, said method according to the present invention is suitable to determine if a subject has or will have improvement of the symptoms of neurotoxicity. The present invention foresees that in the method for evaluating the treatment response of a subject step (iii) is conducted by determining the level of the at least one biomarker for example on protein level and / or on gene level, and then comparing the levels with a suitable reference or control sample or value in a such a way that a difference can be determined. Without to be bound to any theory, it is assumed according to the present invention that a decreased level of CXCR6 and / or CXCL16 is indicative for a beneficial therapeutic effect in the subject. The course of neurotoxicity, preferably of ICANS-associated neurotoxicity, is associated with the increase of CXCR6 and / or CXCL16 expression. It is assumed that said increase decreases in the course of treatment. Therefore, a treatment response can be evaluated with the method for evaluating according to the present invention.

[0068] The method of the present invention allows advantageously to monitor the course of atreatment, i.e. if the treatment provides an amelioration, stagnation, or worsening of the condition of a subject. Preferably, a reduced level of CXCR6 and / or CXCL16 indicates a positive prognosis of the treatment course, whereas an elevated level of CXCR6 and / or CXCL16 indicates a negative prognosis of the treatment course.

[0069] Preferably, it is foreseen according to the method for evaluating the treatment response in a subject that said reference sample of reference value of (iii) corresponds to the level of said at least one biomarker of (ii) in the biological sample of (i) before the subject has received the therapy for treating neurotoxicity.

[0070] In a further preferred embodiment of the present invention, it is foreseen that the subject conducts or has conducted a treatment a treatment with an immune therapeutic agent, preferably an immune effector cell therapeutic agent or a T cell engaging therapeutic agent selected from a CAR-T cell, or an antibody, such as a bispecific antibody, and wherein neurotoxicity is immune effector cell-associated neurotoxicity syndrome (ICANS), ICANS-like neurotoxicity or non-ICANS neurotoxicity.* * * *

[0071] It is noted that as used herein, the singular forms “a”, “an”, and “the”, include plural references unless the context clearly indicates otherwise. Thus, for example, reference to “a reagent” includes one or more of such different reagents and reference to “the method” includes reference to equivalent steps and methods known to those of ordinary skill in the art that could be modified or substituted for the methods described herein.

[0072] Unless otherwise indicated, the term "at least" preceding a series of elements is to be understood to refer to every element in the series. Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the present invention.

[0073] The term "and / or" wherever used herein includes the meaning of "and", "or" and "all or any other combination of the elements connected by said term".

[0074] The term “less than” or in turn “more than” does not include the concrete number.

[0075] For example, less than 20 means less than the number indicated. Similarly, more than or greater than means more than or greater than the indicated number, f.e. more than 80 % means more than or greater than the indicated number of 80 %.

[0076] Throughout this specification and the claims which follow, unless the context requires otherwise, the word “comprise”, and variations such as “comprises” and “comprising”, will beunderstood to imply the inclusion of a stated integer or step or group of integers or steps but not the exclusion of any other integer or step or group of integer or step. When used herein the term “comprising” can be substituted with the term “containing” or “including” or sometimes when used herein with the term “having”. When used herein “consisting of" excludes any element, step, or ingredient not specified.

[0077] The term “including” means “including but not limited to”. “Including” and “including but not limited to” are used interchangeably.

[0078] It should be understood that this invention is not limited to the particular methodology, protocols, material, reagents, and substances, etc., described herein and as such can vary. The terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention, which is defined solely by the claims.

[0079] All publications cited throughout the text of this specification (including all patents, patent application, scientific publications, instructions, etc.), whether supra or infra, are hereby incorporated by reference in their entirety. Nothing herein is to be construed as an admission that the invention is not entitled to antedate such disclosure by virtue of prior invention. To the extent the material incorporated by reference contradicts or is inconsistent with this specification, the specification will supersede any such material.

[0080] The content of all documents and patent documents cited herein is incorporated by reference in their entirety.

[0081] A better understanding of the present invention and of its advantages will be had from the following examples, offered for illustrative purposes only. The examples are not intended to limit the scope of the present invention in any way.EXAMPLES OF THE INVENTION

[0082] Example 1 :

[0083] Clinical characteristics of ICANS patientsWithin our study cohort the inventors included ICANS patients with primary diagnosis of diffuse large B cell lymphoma (5 / 11), B precursor acute lymphoblastic leukaemia (1 / 11), highly malignant B cell lymphoma (1 / 11), mantle cell lymphoma (2 / 11), follicular lymphoma (1 / 11) and multiple myeloma (1 / 11) based on the respective diagnostic criteria. CAR treatment was determined based on ASCO guidelines17 and patients received brexu-cel (3 / 11), axi-cel (7 / 11), cilta-cel (1 / 11) after standardized lymphodepletion. After CAR infusion (day 0), all patients were monitored using a CAR-specific neurologic symptom checklist (NSC). Patients developed cytokine release syndrome (grade 1 to 3) within 3 days (range 1-5 days) of CAR infusion (95% Cl) with signs and symptoms including fever (100%) and hypotension (33%) (Figure 4A). Patients in our cohort developed ICANS within 7 days (range 5 - 21 days) of CAR infusion with varying degrees of severity (ICANS grade 1 to 4). A lumbar puncture was performed for clinical reasons if ICANS was suspected and ICANS patients showed an increased CSF cell count and total protein (Figure 4 B,C) as described previously3. Longitudinal serum IL-6 levels correlated more closely with CRS than with ICANS severity (Figure 4D) as described previously3.

[0084] Example 2:

[0085] Transcriptomic Profiling of CSF Cells Reveal CXCR6 Upregulation and Proliferative Signatures During ICANSThe inventors analyzed CSF samples from five patients at the onset of ICANS (ICANS_onset), including one patient with longitudinal samples collected before CAR T-cell infusion (pre-CART) and after ICANS remission (ICANS_remission). As a control, the inventors included existing CSF cell data from donors with non-inflammatory idiopathic intracranial hypertension (II H).Clustering the cells allowed for the identification of expected immune cell types based on canonical markers (Fig. 1 A and Fig. 5A-B). CSF cells from ICANS patients interspersed with those from IIH controls (Fig. 5C). Most clusters, particularly the non-proliferating cell clusters, were derived from both ICANS and IIH donors, suggesting that variability among samples was less pronounced than variability among cell types (Fig. 5C). The inventors categorized CD4 T cell clusters into two groups based on the percentage of cells expressing the GZMA gene as a proxy of cytotoxicity and activation: Cytotoxic CD4 (>70%) and CD4 (<70%) (Fig. 5D). After thissubsetting, proliferating cells were significantly increased in ICANS_onset samples compared to IIH controls (Fig. 1B-C). While not statistically significant, CSF cells from ICANS_onset patients exhibited a higher proportion of cells in the G2M phase of the cell cycle (Fig. 6A) and showed enrichment in Hallmark gene sets associated with cell proliferation, including G2M checkpoint and E2F targets (Fig. 6B). These proliferative cells were primarily derived from ICANS_onset samples and predominantly consisted of CD4 T cells (Fig. 60). Moreover, cells with an in silico detected CAR transcript (Methods) were mostly present in T cell clusters within ICANS_onset samples (Fig. 1 D, 1F). As expected, no CAR transcripts were detected in IIH samples (Fig. 1F).In addition, the inventors conducted differentially expressed genes (DEGs) analysis between ICANS_onset and IIH samples for each annotated cell type to identify transcriptional alterations in ICANS. Consistently, CXCR6 was upregulated in ICANS patients compared to IIH controls, both in terms of gene expression levels (Fig. 1 E, Fig. 7A) and the percentage of cells expressing CXCR6 across multiple T cell subsets, including proliferating, Cytotoxic CD4, and CD4 cells (Fig.1G-H). Additionally, the inventors found a significant positive correlation between CXCR6 gene expression and the granzyme gene, GZMA, across all T cell subsets during the onset of ICANS, suggesting that upregulation of CXCR6 is associated with increased T cell cytotoxicity (Fig. 7B). KEGG pathway enrichment analysis revealed several top enriched pathways implicated in various aspects of ICANS pathogenesis. Notably, pathways associated with increased energy demand (Oxidative Phosphorylation), cell-cycle regulation (G2M Checkpoint, Myc Target V1, Mitotic Spindle), and inflammatory responses (Interferon Gamma Response, Endocytosis) were among the top enriched pathways identified in the ICANS_onset CSF samples (Fig. 11). These pathways are known to be associated with T cell cytotoxic responses, suggesting their potential involvement in ICANS.The inventors next reconstructed single-cell T cell receptor (TCR) sequence information from these CSF samples. Our analysis revealed a modest predominance of larger clones (10% > clone frequency > 1%) within the Proliferating and CD8 T cell clusters in ICANS_onset samples (Fig.8A-B). Further analysis of proliferating cells from ICANS_onset patients (with nearly no proliferating cells observed in IIH controls) revealed that CAR+ proliferating cells contained a higher proportion of large clonal expansions compared to their CAR- counterparts. Clonal network analysis indicated that Proliferating cells shared a higher clonal proportion with CD8 T cells than with the other two CD4 T cell clusters (Fig. 1J). This phenomenon of CD4 T cell proliferation without significant clonal expansion suggests that the observed increase in CD4+ Proliferating cells is driven not by the rapid replication of a few specific clones but by active division across a diverse array of CD4 T cell clones. Moreover, comparative analysis of clonal diversity across samples and groups revealed significantly higher TCR diversity, as measured by the Chad index, in ICANS_onset patients, corroborating our observations of diverse clonal contributions to the expanded CD4 T cell population.

[0086] Example 3:

[0087] Intercellular Communication and Molecular Pathways in Cytotoxic CD4 T Cells During ICANSThe inventors further explored the intercellular communication within the cell clusters. Differential communication analysis revealed three principal signaling alterations in Cytotoxic CD4 T cells, specifically involving the CXCL, IL16, and CD40 pathways (Fig. 2A). These changes were predominantly driven by the CXCL16-CXCR6, IL16-CD4, and CD40LG-(ITGAM+ITGB2) axes, respectively (Fig. 2B). Notably, the top differential incoming signaling was mediated by CXCL for Proliferating, Cytotoxic CD4, and CD4 cells in ICANS_onset CSF (Fig. 2A), and the potential source of this CXCL signal (CXCL16) was identified to be CNS-associated myeloid cells (CAM) (Fig. 2B). Indeed, when the inventors examined the temporal dynamics of the expression of CXCL16 chemokine as well as fractions of CAR_transcript+ and CXCR6+ cells from pre-CART infusion to ICANS_onset and ICANS_remission among the Proliferating, Cytotoxic CD4, and CD4 cells of one patient, the inventors observed peaking expression around the onset of ICANS over time (Fig. 9A-B). The expression levels of GZMA, GZMB, and CXCR6 genes decreased in ICANS_remission compared to ICANS_onset (Fig. 9C). The temporal dynamics of CXCR6-expressing cytotoxic T cells thus mirror the development of ICANS suggesting their mechanistic relevance in the disease.To investigate ICANS-associated alterations across different compartments and confirm transcriptional data on protein level, the inventors next performed multicolor flow cytometry on paired CSF and blood samples from seven ICANS patients at disease onset. Consistent with our scRNA-seq findings, the inventors observed a significantly higher proportion of CD4 T cells in the CSF compared to the blood of ICANS patients, reflected by increased CD4 / CD8 ratios in the CSF (Fig. 2C, Fig. 10 A-B). This enrichment of CD4 T cells within the CNS compartment was not present in most II H donors without neuroinflammation, but evident in the CAR T cell fraction (Fig.10C). Moreover, a significantly higher percentage of specifically CAR+CXCR6+ CD4 T cells was detected in the CSF of ICANS patients compared to their paired blood samples, while CAR+CXCR6+ CD8 T cells did not show a difference (Fig. 2D, Fig. 10D-F, 8A-B). Longitudinal analysis of T cells from one patient revealed the reappearance of CAR+CXCR6+ CD4 and CD8 blood T cells after passing the CRS maximum with a selective increase of CAR+CXCR6+ CD4 T cells in the CSF during ICANS (Fig. 11B-C), highlighting the critical role of CXCR6 as a specific receptor that drives the preferential accumulation of cytotoxic CD4 CAR T cells in the CNS during ICANS onset. Indeed, although CD4 CAR T cells in the CSF presented a more activatedphenotype by expressing other activation markers such as CD69 and GZMA compared to the blood (Fig. 12 A-D), only CXCR6 showed a specific increase on CAR+ T cells within the CSF compared to CAR- T cells (Fig. 12E-G).CXCR6 is activated by its ligand CXCL16. The inventors detected a significant correlation between CSF CXCL16 levels and ICANS severity (Fig. 2E, Fig. 13A), with no similar association for CSF IL-6 levels (Fig. 13B), despite a correlation between IL-6 and CXCL16 levels (Fig. 2F). These results suggest a divergence between systemic and CNS inflammation, implicating the CXCL16 / CXCR6 axis as a specific contributor to ICANS pathophysiology and soluble CXCL16 as a possible versatile future disease biomarker.

[0088] Example 4:

[0089] Elucidating the Role of the CXCL16-CXCR6 Axis in T Cell Infiltration and ICANS PathologyThe inventors aimed to confirm the presence of CXCL16 ligand and CXCR6+ T cells at the protein level in ICANS-affected brain tissues, and conducted conventional immunohistochemistry on choroid plexus samples from an ICANS patient who had died following severe cerebral edema. This demonstrated the presence of both CXCR6+ and CXCL16+ cells (Fig. 3A). Further investigation into the cellular sources of the CXCL16 signal was carried out using high-resolution spatial transcriptomic analysis (Methods), which highlighted extensive CXCL16 expression across the choroid plexus (Fig. 14A). This CXCL16 expression was spatially associated with myeloid cell markers such as CD14 (Fig. 14B), along with activation markers CD40 (Fig. 14C) and CD68 (Fig. 14D). A substantial fraction of these cells expressed integrins ITGAL (CD11a, Fig. 14E) and ITGA4 (CD49d, Fig. 14F), key facilitators of myeloid cell migration across the bloodbrain barrier in response to inflammation18-20, while a lower proportion of cells displayed markers of resident microglia, including CX3CR1 (Fig. 14G) and TMEM119 (Fig. 14H). Explorative flow cytometric analysis of an additional ICANS patient (ICANS grade 2, day 5 after brexu-cel therapy) confirmed a cross compartment shift of activated classical monocytes upregulating CD40 and CD49d from blood to the CSF (Fig. 141). This suggests that infiltrating myeloid cells, rather than resident microglia, are most likely to produce CXCL16 in the ICANS-affected choroid plexus and thus may attract CXCR6-expressing T cells.Due to the significant autofluorescence of ependymal cells complicating multiplex immunofluorescence (mIF) staining in choroid plexus tissues, the inventors conducted mIF analysis on post-mortem periventricular brain tissues (basal ganglia) harvested from the same ICANS patient (Fig. 15A). Their results revealed CXCR6+CD3+ T cells within regions of the brain parenchyma that also exhibited considerable CXCL16+ signals (Fig. 3B-E, Fig. 15B). Positioned near these T cells were CXCL16+CD11b+ myeloid cells, which also expressed IL-18 (Fig. 3C), acytokine known to enhance cell-mediated cytotoxicity in neurodegenerative conditions21. Additionally, these CXCR6+CD3+ T cells demonstrated elevated Ki-67 levels, indicative of an active proliferative state congruent with our scRNA-seq data (Fig. 3D). Notably, the inventors observed an elevated proximity ratio of CXCR6+CD3+ T cells to CXCL16+CD11b+ myeloid cells when compared to CXCL16-CD11b+ myeloid cells (Fig. 3E). In addition, by comparing CAR+ and CAR- T cells, the inventors verified that CXCR6 protein and gene expression was significantly increased in CSF CAR-expressing CD4 T cells in ICANS_onset patients (Fig. 12E, Fig. 16). Together, these findings underscore the potential pivotal role of the CXCL16-CXCR6 axis in propagating T cell infiltration into the CNS during ICANS.The experimental data of the invention provides insights into the cellular and molecular profiles of immune cells within the CSF of ICANS patients undergoing CAR T cell therapy, enhancing the inventors understanding of ICANS pathophysiology and pointing towards potential therapeutic avenues. The inventors noted an enrichment of CD4 CAR T cells in the CSF of ICANS patients, particularly those expressing CXCR6. These cells exhibited a more activated, cytotoxic profile compared to their counterparts in the blood. The inventors’ observations suggest that CXCR6+ CAR CD4 T cells may play a role in mediating cytotoxic responses within the CNS, potentially contributing to ICANS by their proximity to CXCL16+IL-18+ myeloid cells and their apparent proliferative activity. This aligns with the hypothesis that ICANS involves a multifaceted interaction among immune effector cells, cytokine signaling, and the BBB2.The association the inventors observed between CXCR6 expression and ICANS severity, together with the temporal dynamics of CXCR6+ CAR T cells during disease onset, hint at the possible significance of the CXCL16 / CXCR6 axis in driving neuroinflammation in ICANS. The inventors’ findings support existing literature suggesting that systemic cytokine levels, such as IL-6, do not completely explain the severity and progression of neurotoxicity6’10’16; rather, local inflammatory processes within the CNS, particularly involving the CXCL16 / CXCR6 axis, appear to have a more defining role. The identification of CXCR6-expressing cytotoxic T cells and CXCL16-expressing myeloid cells in the choroid plexus and CSF as central elements in this process provides valuable insights into the cellular interactions that may underpin BBB disruption and CNS inflammation in ICANS.Moreover, the inventors’ spatial transcriptomics and immunohistochemistry analysis suggested that CXCL16 is primarily produced by myeloid cells within the CNS, proposing a route through which these cells could recruit and stimulate CXCR6+ T cells in regions affected by ICANS. This local increase in pro-inflammatory myeloid cytokines, such as IL-1821’23, which can co-stimulate INF-y production, further implies a role for these cells in amplifying cytotoxic immune responses, potentially exacerbating neuroinflammation. These insights underscore the possibility of targeting the CXCL16 / CXCR6 signaling pathway as a means to attenuate ICANS while preserving the systemic immune responses critical for CAR T cell therapy's effectiveness.The inventors found out that CXCR6 expression is notably elevated in ICANS patients, endorsing the specificity of this axis in neurological complications linked to treatment.In conclusion, the experimental data of the invention identified the CXCL16 / CXCR6 axis as a contributory factor in ICANS pathophysiology, pointing to the recruitment and activation of cytotoxic CXCR6+CD4 CAR T cells in the CNS as a potential pathway driving neuroinflammation. This insight provides a foundation for potentially using this axis as a biomarker for disease severity and a therapeutic target. While ICANS is currently managed primarily through corticosteroids and IL-6 blockade, the experimental data of the invention suggest exploring more targeted interventions aimed at disrupting the CXCL16 / CXCR6 axis to possibly prevent or alleviate ICANS more effectively, without impacting the therapeutic benefits of CAR T cell therapy.

[0090] Example 5:

[0091] MethodsPatients

[0092] All participants received treatment utilizing commercially available CAR-T cell products. Prior to enrolment, written informed consent was obtained from each patient, following approval from the Ethics Committee of the Board of Physicians of the Region Westfalen-Lippe and the University of Munster (reference: 2015-522-f-S, 2021-198-f-S, 2024-345-f-S). Clinical data and CSF samples were collected in accordance with ethical guidelines and the principals of the Helsinki declaration. Within our clinical cohort (scRNA-Seq, FACS, ELISA and autopsy material) ICANS patients were initially diagnosed with a diffuse large B cell lymphoma (5 / 11), a B precursor acute lymphoblastic leukaemia (1 / 11), a highly malignant B cell lymphoma (1 / 11) ora mantle cell lymphoma (2 / 11) based on the respective diagnostic criteria. One patient was diagnosed with a multiple myeloma (1 / 11) and received consecutively anti-BCMA CAR T cell therapy (cilta-cel, Carvykti). Most patients (7 / 11) were in Ann Arbor stages of >3 with a poor prognosis in the international prognostic index2627. All other patients received treatment with brexu-cel (T ecartus®) or axi-cel (Yescarta®) after a standardized lymphodepletion of cyclophosphamide / fludarabine. After CAR Infusion (day 0) patients were monitored with a CAR specific neurological symptom checklist (NSC) and treated according to clinical standard operation procedures and current guidelines17’2829. Patients developed cytokine release syndrome (grade 1 to 3) within 3 days (range 1-5 days) of CAR infusion with signs and symptoms including fever (100%) and hypotension (33%) (Fig. 4A). Patients developed ICANS11within 7 days (range 5 - 21 days) of CAR infusion with varying degrees of severity (ICANS grade 1 (3 / 11), grade 2 (4 / 11), grade 3 (1 / 11), grade 4 (3 / 11)) (Fig. 4A). A lumbar puncture was performed for clinical reasons if ICANS was suspected and ICANS patients showed an increased CSF cell count and total protein (Fig.4B-C) as described previously3. Serum IL-6 levels correlated closely with CRS (Fig. 4D) as described previously3.

[0093] Sample preparation

[0094] All lumbar punctures were conducted under strict sterile conditions and performed for clinical reasons. CSF samples were meticulously collected in sterile tubes utilizing the Sprotte spinal needle, with processing within a 2-hour window post lumbar puncture to uphold sample integrity. Upon collection, CSF was carefully transferred into round-bottom polypropylene tubes and subsequently centrifuged at 300x g for 10 minutes. The resulting cell-free supernatants were delicately withdrawn using a pipette, then preserved at -80°C for subsequent proteomic analysis. The CSF-cell pellet was resuspended in autologous CSF and gently diluted into 500|JL of RPMI-1640 supplemented with 40% FBS. For cryopreservation, the CSF-cell suspension was slowly diluted dropwise with 500|JL of pre-chilled freezing medium comprising RPMI-1640 supplemented with 40% FBS and 20% DMSO. Subsequently, the CSF sample was expeditiously placed within a freezing container (Mister Frosty, Thermo Fisher) and stored overnight in a -80°C freezer prior to transfer to liquid nitrogen (LN) storage. For the thawing of cryopreserved CSF cells, the samples were carefully retrieved from the LN and thawed at 37°C for 1-2 minutes, allowing for the presence of a tiny ice crystal within the cryotube. The cells were then diluted 1:10 in PBS supplemented with 10% FBS and subjected to centrifugation at 300g for 10 minutes at 4°C. After discarding the supernatant, the cells were resuspended in 50|JL of PBS, with 10pL reserved for cell counting purposes. The remaining cells were then processed for 5'-single cell RNA sequencing.

[0095] Single-cell sequencing and data pre-processing

[0096] Single-cell suspensions were loaded onto the Chromium Single Cell Controller according to the manufacturer’s instructions. The scRNA-seq libraries were processed using Chromium single-cell 5' library and gel bead kit v.2 (10x Genomics) and coupled scTCR-seq libraries were successfully obtained from all samples except one using Chromium single-cell V(D)J enrichment kit (human T cell) (10x Genomics). Quantification was conducted with precision using the TapeStation High Sensitivity D1000 kit (Agilent) to ascertain the average fragment size and library concentration. Subsequently, the libraries underwent normalization, dilution, and were sequenced on a local Nextseq 2000 using the P3 100 cycle kit with a 28-10-10-90 read setup. To process the sequencing data, a customized reference was constructed by incorporating the previously characterized CAR gene sequences30for both axi-cel and brexu-cel, which originated from msgv-fmc63-28z31, into the GRCh38 reference genome. This custom reference was prepared using Cellranger mkref (version 7.2.0) adhered to the manufacturer’s instructions. Raw bcl files were then de-multiplexed using the cellranger mkfastq pipeline. Subsequent read alignments andtranscript counting were done individually for each sample using the cellranger count pipeline using the custom reference described above.

[0097] Single-cell analysis

[0098] Single-cell analysis was conducted using Seurat v532in R version 4.3.2. Pooled samples from individuals with II H were demultiplexed employing Vireo33, a genotype-based demultiplexing method. The cellranger matrix was loaded into Seurat. SoupX341.6.2 was carried out with the automatic method using clustering information to reduce ambient RNA expression. Cells were filtered for less than 5% mitochondrial RNA transcripts, a minimum of 200 genes and a maximum of 3500 feature genes for each sample based on inspection of the QC plots. Next, the inventors normalized the samples separately with SCTransform v235and then removed the batch effect with Harmony36. Clusters and LIMAP embeddings were computed based on the Harmony reduction within Seurat using a resolution of 1.2 and 40 dimensions. The resulting 23 clusters were subsequently categorized into 6 distinct cell types based on their respective marker genes. Predicted classification of each cell in either G2M, S or G1 cell-cycle phase was done by CellCycleScoring function, and fractions of CAR_transcript- and CXCR6-expressing cells were calculated through the PercentageFeatureSet function within the Seurat package. Dot plots and feature plots were generated with Seurat functions based on the log-normalized data. CellChat26R package was utilized to investigate and visualize cell-cell communication and ligand-receptor interactions among different CSF cells using standard package functions.

[0099] Analysis of differential cell abundances and gene expression

[0100] Differential abundance (DA) was determined with the propeller38tool, which is part of speckle v1.0.0. Briefly, the inventors transformed the cell type proportions with a logit function. When comparing ICANS_onset to II H, the inventors build a linear model adjusting for gender and age. The inventors computed significance based on the robust empirical Bayes method from limma. P values were adjusted with the Benjamini Hochberg method. Following this, differentially expressed genes (DEGs) analysis at the pseudobulk level was conducted between ICANS_onset and IIH as well as between CXCR6+ and CXCR6- cells employing DESeq2 through the FindMarkers function within the Seurat package. The DA and DEGs results were visualized with ggplot2.

[0101] Gene set enrichment analysis (GSEA)

[0102] Significantly regulated genes were identified by adjusted p-value < 0.05 following the DEGs analysis and were further input into GSEApy39version 1.1.2 in Python version 3.10.0 for enrichment analysis using KEGG pathways gene sets, including MSigDB_Hallmark_2020 and KEGG_2021_Human. The enrichment scores across all individual cells and groups were computed by the enrichlt function of the escape package and were visualized with dittoSeq package.

[0103] Single-cell immune repertoire analysis

[0104] Single-cell T cell receptor sequencing (scTCR) data was analyzed using scRepertoire v2.04° and immunarch vO.9.141. The filtered outputs of CellRanger vdj were imported, and the TCR heavy and light chains were combined in each cell based on their barcodes. Cells with more than two immune receptor chains were removed from the dataset. Clonotypes were called using the CDR3 amino acid sequence.

[0105] Flow cytometry

[0106] The inventors screened all patients who were admitted to the University Hospital Munster between 2022 and 2024 and received CART cell therapy. All samples collected during regular working hours at the center in Munster were promptly analyzed by flow cytometry using a Navios flow cytometer (Beckman Coulter). Briefly, blood cells were lysed using VersaLyse buffer and blood and CSF cells were stained using the following anti-human antibodies (clone names indicated): CD3 (SK7); NCAM (HCD56), CD69 (FN50) Granzyme A(CB9), CXCR6 (K041E5); Beckman Coulter: CD4 (SFCI12T4D11), CD8 (A99019) CD45RA (A07786), CD45 (B36294); Miltenyi Biotec CD19-CAR FMC63 Idiotype Antibody (REA1297), The gating scheme is depicted in Extended Data Fig. 7A-B. Cell population size was defined as the number of gated cell events relative to the events of the corresponding parent gate.

[0107] ELISA

[0108] An Enzyme linked immunosorbent assay (ELISA) (R&D Systems Human CXCL16 ELISA Kit-Quantikine #DCX160) was performed according to manufacturer's instructions. In brief, CSF supernatents were processed as shown previously here and aliquots were stored at -80 °C. For analysis, samples were thawed and after a dilution series used in a final dilution of 1:4 in a96 well plate. Samples were measured in technical duplicates in a Tecan Plate reader Infinite M200pro (Tecan) at a wavelength of 450 nm with a reference at 620 nm. The aliquots used have not been repeatedly frozen / thawed prior to this study. The intra-assay variance was at 2.6%.

[0109] Immunohistochemistry

[0110] Seven-color multiplexed immunohistochemistry was performed on one postmortem formalin-fixed paraffin-embedded (FFPE) ICANS brain sample with lethal ICANS grade 4 syndrome using the Opal multiplex system21(Akoya Biosciences). In brief, FFPE sections of 2-pm thickness were deparaffinized and then fixed with 4% paraformaldehyde prior to antigen retrieval by heat-induced epitope retrieval using citrate buffer (pH6) or Tris / EDTA (pH9). After cooling down from antigen retrieval, slides were immersed in alkaline hydrogen peroxide solution (pH11.5) in transparent plasticware and exposed to white light by sandwiching the immersed slides between two light-emitting diode (LED) panels. The slides were incubated for 45 min, after that the solution was discarded and replaced by freshly prepared hydrogen peroxide solution for another 45min LED exposure. Slides were then washed with PBS and ready for subsequent staining. Each section was put through several sequential rounds of staining; each included endogenous peroxidase blocking and non-specific protein blocking, followed by primary Ab and corresponding secondary horseradish peroxidase-conjugated polymer (Zytomed Systems, Germany or Akoya Biosciences). Each horseradish peroxidase-conjugated polymer mediated the covalent binding of different fluorophores using tyramide signal amplification. Such covalent reaction was followed by additional antigen retrieval in heated citric buffer (pH6) or Tris / EDTA (pH9) for 10 min to remove antibodies before the next round of staining. After all sequential staining reactions, sections were counterstained with DAPI (Vector lab). Slides were subsequently scanned and digitalized by Zeiss AxioScanner Z.1 (Carl Zeiss AG) with *10 objective magnification. Quantification of co-expressing markers and proximity analysis were performed with HALO (Indica Labs). Four regions of interest (ROIs), each measuring 1000 pm x 1000 pm, were selected within brain parenchyma areas exhibiting T cell infiltration (Supplementary Fig. 12A). The proportion of CXCR6+ CD3+ DAPI+ cells located within a 100 pm proximity to either CXCL16+ CD11b+ DAPI+ cells or CXCL16- CD11b+ DAPI+ cells was calculated. Cell counts were quantified within each ROI to determine these ratios.

[0111] Spatial gene expression assay and data pre-processing

[0112] 5 pm FFPE serial sections were placed on standard glass slides and H&E-stained and processed following the manufacturer’s instructions (Visium HD by 10X Genomics). The CytAssist instrument was used to facilitate the transfer of transcriptomic probes from the standardglass slide to the Visium HD Spatial Gene Expression slide with 6.5 x 6.5 mm capture area. Sequencing was performed on the NextSeq 2000 with a 43-10-10-50 read setup. Flow cells were demultiplexed using the mkfastq command in Space Ranger v3.0.1 (10X Genomics), and FASTQs were aligned to the human (GRCh38) reference. Feature plots were generated with Seurat SpatialFeaturePlot function and with ggplot2 using the dataset with 8 pm bins.REFERENCESJune, C. H. & Sadelain, M. Chimeric Antigen Receptor Therapy. N. Engl. J. Med. 379, 64-73 (2018).Morris, E. C., Neelapu, S. S., Giavridis, T. & Sadelain, M. Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy. Nat. Rev. Immunol. 22, 85-96 (2022). Neelapu, S. S. et al. Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. Nat. Rev. Clin. Oncol. 15, 47-62 (2018).Turtle, C. J. etal. Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells. Sci. Transl. Med. 8, 355ra116 (2016).Turtle, C. J. etal. Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 35, 3010-3020 (2017).Gust, J. etal. Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells. Cancer Discov. 7, 1404-1419 (2017). Maude, S. L. etal. Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. N. Engl. J. Med. 378, 439-448 (2018).Strati, P. et al. Clinical efficacy of anakinra to mitigate CAR T-cell therapy-associated toxicity in large B-cell lymphoma. Blood Adv. 4, 3123-3127 (2020).Chen, L.-Y. etal. Successful application of anti-CD19 CAR-T therapy with IL-6 knocking down to patients with central nervous system B-cell acute lymphocytic leukemia. Transl. Oncol. 13, 100838 (2020).Gust, J. etal. Glial injury in neurotoxicity after pediatric CD19-directed chimeric antigen receptor T cell therapy. Ann. Neurol. 86, 42-54 (2019).Santomasso, B. D. et al. Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia. Cancer Discov.8, 958-971 (2018).Norelli, M. etal. Monocyte-derived IL-1 and IL-6 are differentially required for cytokinerelease syndrome and neurotoxicity due to CAR T cells. Nat. Med. 24, 739-748 (2018). Parker, K. R. et al. Single-Cell Analyses Identify Brain Mural Cells Expressing CD19 as Potential Off-Tumor Targets for CAR-T Immunotherapies. Cell 183, 126-142.e17 (2020). Van Oekelen, O. etal. Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy. Nat. Med. 27, 2099-2103 (2021). Le, R. Q. etal. FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release Syndrome. The Oncologist 23, 943-947 (2018).Maus, M. V. etal. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events. J. Immunother. Cancer8, e001511 (2020). Santomasso, B. D. etal. Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO Guideline. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 39, 3978-3992 (2021).Shukla, A. K. etal. CD11a expression distinguishes infiltrating myeloid cells from plaque-associated microglia in Alzheimer’s disease. Glia 67, 844-856 (2019).Wilk, C. M. etal. Circulating senescent myeloid cells infiltrate the brain and cause neurodegeneration in histiocytic disorders. Immunity 56, 2790-2802. e6 (2023).Bowman, R. L. etal. Macrophage Ontogeny Underlies Differences in Tumor-Specific Education in Brain Malignancies. Cell Rep. 17, 2445-2459 (2016).Lu, l.-N. etal. Cell-mediated cytotoxicity within CSF and brain parenchyma in spinal muscular atrophy unaltered by nusinersen treatment. Nat. Commun. 15, 4120 (2024). Qin, C. etal. Single-cell analysis of anti-BCMA CAR T cell therapy in patients with central nervous system autoimmunity. Sci. Immunol. 9, eadj9730 (2024).Alboni, S., Cervia, D., Sugama, S. & Conti, B. Interleukin 18 in the CNS. J.Neuroinflammation 7, 9 (2010).Aguilera-Duran, G. & Romo-Mancillas, A. Behavior of Chemokine Receptor 6 (CXCR6) in Complex with CXCL16 Soluble form Chemokine by Molecular Dynamic Simulations:General Protein-Ligand Interaction Model and 3D-QSAR Studies of Synthetic Antagonists. Life 11, 346 (2021).Peddibhotla, S. etal. Discovery of small molecule antagonists of chemokine receptor CXCR6 that arrest tumor growth in SK-HEP-1 mouse xenografts as a model of hepatocellular carcinoma. Bioorg. Med. Chem. Lett. 30, 126899 (2020).Hoster, E. etal. A new prognostic index (Ml PI) for patients with advanced-stage mantle cell lymphoma. Blood 111, 558-565 (2008).Sehn, L. H. etal. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard I PI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 109, 1857-1861 (2007).Lee, D. W. et al. ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. Biol. Blood Marrow Transplant. J. Am. Soc. Blood Marrow Transplant. 25, 625-638 (2019).Hayden, P. J. etal. Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA). Ann. Oncol. 33, 259-275 (2022).Haradhvala, N. J. etal. Distinct cellular dynamics associated with response to CAR-Ttherapy for refractory B cell lymphoma. Nat. Med. 28, 1848-1859 (2022).31. Kochenderfer, J. N. etal. Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor. J. Immunother. Hagerstown Md 199732, 689-702 (2009).32. Hao, Y. et al. Dictionary Learning for Integrative, Multimodal, and Scalable Single-Cell Analysis. http: / / biorxiv.Org / lookup / doi / 10.1101 / 2022.02.24.481684 (2022)doi:10.1101 / 2022.02.24.481684.33. Huang, Y., McCarthy, D. J. & Stegle, O. Vireo: Bayesian demultiplexing of pooled single-cell RNA-seq data without genotype reference. Genome Biol. 20, 273 (2019).34. Young, M. D. & Behjati, S. SoupX removes ambient RNA contamination from droplet-based single-cell RNA sequencing data. GigaScience 9, giaa151 (2020).35. Choudhary, S. & Satija, R. Comparison and evaluation of statistical error models for scRNA- seq. Genome Biol. 23, 27 (2022).36. Korsunsky, I. etal. Fast, sensitive and accurate integration of single-cell data with Harmony.Nat. Methods 16, 1289-1296 (2019).37. Jin, S. et al. Inference and analysis of cell-cell communication using CellChat. Nat.Common. 12, 1088 (2021).38. Phipson, B. et al. propeller: testing for differences in cell type proportions in single cell data.Bioinforma. Oxf. Engl. 38, 4720-4726 (2022).39. Fang, Z., Liu, X. & Peltz, G. GSEApy: a comprehensive package for performing gene set enrichment analysis in Python. Bioinforma. Oxf. Engl. 39, btac757 (2023).40. Borcherding, N., Bormann, N. L. & Kraus, G. scRepertoire: An R-based toolkit for single-cell immune receptor analysis. F1000Research 9, 47 (2020).41. Vadim I. Nazarov and Vasily O. Tsvetkov and Siarhei Fiadziushchanka and Eugene Rumynskiy and Aleksandr A. Popov and Ivan Balashov and Maria Samokhina, immunarch: Bioinformatics Analysis of T-Cell and B-Cell Immune Repertoires. (2023).Tsuchikama et al., Nature Reviews Clinical Oncology, Volume 21, March 2024, 203-223 B.S. Chandrasekar, S. Mummidi, CXCL16 signals via Gi, phosphatidylinositol 3-kinase, Akt, IKB kinase, and nuclear factor-KB and induces cell-cell adhesion and aortic smooth muscle cell proliferation, J. Biol. Chem. 279 (2003) 3188-3196. E. Galkina, B.L. Harry, A. Ludwig, E.A. Lieh, J.M. Sanders, A. Bruce, C. Weber, K. Ley, CXCR6 promotes atherosclerosis by supporting T-cell homing, interferonproduction, and macrophage accumulation in the aortic wall, Vase. Med. 116 (2007) 1801-1811.T. Shimaoka, T. Nakayama, N. Fukumoto, N. Kume, S. Takahashi, J. Yamaguchi, M. Minami, K.Hayashida, T. Kita, J. Ohsumi, O. Yoshie, S. Yonehara, Cell surface-anchored SR- PSOX / CXC chemokine ligand 16 mediates firm adhesion of CXC chemokine receptor 6- expressing cells, J. Leukoc. Biol. 75 (2003) 267-274.Bona Linke, Sascha Meyer Dos Santos, Bettina Picard-Willems, Michael Keese, Sebastian Harder, Gerd Geisslinger, Klaus Scholich, CXCL16 / CXCR6-mediated adhesion of human peripheral blood mononuclear cells to inflamed endothelium, Cytokine, Volume 122, 2019, 154081 , ISSN 1043-4666, https: / / doi.Org / 10.1016 / j.cyto.2017.06.008.

Claims

CLAIMS1. A method for the diagnosis, prognosis, stratification and / or monitoring of progression of neurotoxicity in a subject, said method comprising the steps of:(i) providing a biological sample of the subject;(ii) determining the level of at least one biomarker selected from the group consisting of CXCR6 and CXCL16 in the biological sample,wherein a differential level of the at least one biomarker of (ii) compared to a control sample is indicative for the presence of neurotoxicity in the subject.

2. The method of claim 1, wherein the subject conducts or has conducted a treatment with an immune therapeutic agent, preferably an immune effector cell therapeutic agent or a T cell engaging therapeutic agent selected from a CAR-T cell, an antibody, preferably a bispecific antibody.

3. The method of any claim 1 or 2, wherein the neurotoxicity is immune effector cell- associated neurotoxicity syndrome (ICANS), ICANS-like neurotoxicity or non-ICANS neurotoxicity.

4. The method of any one of the claims 1 to 3, wherein the biological sample is a sample of a subject comprising a body liquid sample, such as cerebrospinal fluid (CSF), blood, serum, plasma, lymph fluid, pleural fluid, tear fluid, urine, or a tissue sample, such as a nerve or brain biopsy, a meningeal biopsy, a skin biopsy, or a biopsy from any other tissue containing neuronal material, in particular preferred wherein the biological sample is CSF.

5. The method of any one of the preceding claims, wherein determining of the at least one biomarker in step (ii) is conducted by one or more of the methods selected from single cell and bulk RNA sequencing, DNA sequencing, quantitative PCR, differential gene expression analysis, methylation microarrays, spatial transcriptomics, quantitative PCR, proteomic assays, multiplex proteomic assays, metabolic assays, mass spectrometry, multicolour flow cytometry, enzyme-linked immunosorbent assay (ELISA), immunohistochemistry and fluorescence in situ hybridisation (FISH).

6. The method of any one of the preceding claims, wherein in step (ii) one or more further biomarker are determined selected from the group consisting ofa CAR transcript;one or more marker of T cells, in particular selected from CD3, CD4, CD8, and FoxP3;37one or more marker of myeloid cells, in particular selected from CD11a, CD11b, CD11c, CD14, CD15, CD33, CD49d, CD64, CD66b, CD68, CD115, CD155, CD163, CD206, TMEM119 and CX3CR1;one or more activation marker, in particular selected from CD25, CD69, CD127, and HLA-DR;one or more costimulatory or inhibitory marker, in particular selected from CD27, CD28, CTLA4, CD40, CD70, CD80, CD86, CD134, CD137, CD226, CD274, CD279, LAG3, TIM-3, VISTA, ICOS, TIGIT, and its ligands;one or more cytotoxic markers, in particular selected from CD 107a, granzymes, preferably GZMA and / or GZMB, and lysozymes; andone or more of IL (Interleukin)- 1 , IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IL-16, IL-17, IL-18, IL-19, IL-20, IL-21, IL-22, IL- 23, IL-24, IL-25, IL-26, IL-27, IL-28, IL-29, IL-31, IL-32, IL-33, IL-34, IL-35, IL-36, IL-37, IL-38 and its receptors, INF (Interferon)-alpha, INF-beta and INF gamma and its receptors, CCL1, CCL2, CCL3, CCL3L1, CCL3L3, CCL4, CCL4L1, CCL4L2, CCL5, CCL6, CCL7, CCL8, CCL9, CCL10, CCL11, CCL12, CCL13, CCL14, CCL15, CCL16, CCL17, CCL18, CCL19, CCL20, CCL21, CCL22, CCL23, CCL24, CCL25, CCL26, CCL27, CCL28, CXCL1, CXCL2, CXCL3, CXCL4, CXCL4L1, CXCL5, CXCL6, CXCL7, CXCL8, CXCL9, CXCL10, CXCL11, CXCL12, CXCL13, CXCL14, CXCL15, CXCL17, CX3CL1, XCL1, XCL2 and its receptors, Ki-67, PCNA and MCM.

7. The method of any one of the preceding claims, wherein determining of further risk factors for the development of neurotoxicity is conducted, preferably by determining the score of CRS and / or ICANS.

8. A diagnostic kit for conducting a method according to any one of the preceding claims, the diagnostic kit comprising binding molecules for CXCR6 and / or CXCL16 and optional suitable means for detection.

9. Use of a binding molecule for CXCR6 and / or CXCL16 for identifying a subject being at risk for developing a neurotoxicity, preferably wherein the neurotoxicity is selected from ICANS, ICANS-like neurotoxicity or non-ICANS neurotoxicity.

10. A therapeutic agent for use in a method of treating or preventing neurotoxicity in a subject, said subject is characterized by:(i) a treatment with an immune therapeutic agent is intended, is conducted or has been conducted in said subject;(ii) a differential level of CXCR6 and / or CXCL16 in a biological sample of said subjectcompared to a control sample has been determined in said subject; wherein the therapeutic agent comprises one or more selected from a steroid, a glucocorticoid, a CXCR6 binding molecule, a CXCL16 binding molecule, an IL-6 binding molecule, an IL-6R binding molecule, and an IL-1 R binding molecule.

11. The therapeutic agent for use of claim 10, wherein the immune therapeutic agent is an immune effector cell therapeutic agent or a T cell engaging therapeutic agent, preferably a CAR-T cell, an antibody, preferably a bispecific antibody.

12. The therapeutic agent for use of claim 10 or 11, wherein neurotoxicity is immune effector cell-associated neurotoxicity syndrome (ICANS), ICANS-like neurotoxicity or non-ICANS neurotoxicity.

13. A method for evaluating the treatment response of a subject who received a therapy for treating neurotoxicity, said method comprising:(i) providing a biological sample of a subject,(ii) determining the level of at least one biomarker selected from the group consisting of CXCR6 and CXCL16 in the biological sample,(iii) comparing the level of said at least one biomarker in (ii) with a reference sample or reference value;wherein a decrease of the level of the biomarker in the biological sample from said subject compared to said reference sample or reference value is indicative for a treatment response of the subject to said therapy.

14. The method of claim 13, wherein said reference sample of reference value of (iii) corresponds to the level of said at least one biomarker of (ii) in the biological sample of (i) before the subject has received the therapy for treating neurotoxicity.

15. The method of claim 13 or 14, wherein the subject conducts or has conducted a treatment with an immune therapeutic agent, preferably an immune effector cell therapeutic agent or a T cell engaging therapeutic agent selected from a CAR-T cell, or an antibody, such as a bispecific antibody, and wherein neurotoxicity is immune effector cell-associated neurotoxicity syndrome (ICANS), ICANS-like neurotoxicity or non-ICANS neurotoxicity.